AHA 2012.
The most relevant articles and presentations, daily report from the AHA 2012 congress, held in Los Angeles from the 4th to 7th November 2012.
FREEDOM trial: CABG versus angioplasty treatment for diabetic patients with multivessel disease
The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We ...
The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at surgeon discretion), or CABG. We ...
TRILOGY Trial: First large scale test evaluating platelet function in acute coronary syndromes.
TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel versus aspirin + prasugrel in patients admitted ...
TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel versus aspirin + prasugrel in patients admitted ...
TACT trial: Chelation Therapy for the Treatment of Coronary Disease.
In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol content, and oxidative ...
In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol content, and oxidative ...
Artic Study: Bedside Platelet Function Monitoring to Reduce Events after DES Implantation .
Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority of ...
Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority of ...
CPORT-E: Comparison of percutaneous treatment cost in hospitals with and without central vascular surgery.
A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed for 9 months and the costs were evaluated. Mortality and the occurrence of events ...
A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed for 9 months and the costs were evaluated. Mortality and the occurrence of events ...
GAUSS trial: Antibodies for the treatment of hypercholesterolemia in patients with statin intolerance.
Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are statin intolerant or present adverse effects at high doses (especially muscle damage). ...
Statins are the most effective treatment to reduce LDL levels and cardiovascular risk, 10-20% of patients are statin intolerant or present adverse effects at high doses (especially muscle damage). ...
PHS II Trial: Use of multivitamins in the prevention of cardiovascular disease in men.
Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized double blind placebo controlled trial to evaluate the long term effect of the use of ...
Observational studies have shown contradicting results on the use of multivitamins. PHS II is the only randomized double blind placebo controlled trial to evaluate the long term effect of the use of ...
UMPIRE Trial: the polypill proves effective in treating high risk patients.
A polypill is an interesting strategy for cardiac patients requiring multiple drugs. This trial involved 2138 patients from 28 sites in India and Europe with an event risk higher than 15% at 5 years ...
A polypill is an interesting strategy for cardiac patients requiring multiple drugs. This trial involved 2138 patients from 28 sites in India and Europe with an event risk higher than 15% at 5 years ...
OPERA Trial: Use of Omega 3 to prevent post-operative atrial fibrillation
Atrial fibrillation (AF) prolongues post-operative central vascular surgery, increasing morbidity and costs. Though smaller, a few trials have shown positive results for Omega-3 fatty acids. This ...
Atrial fibrillation (AF) prolongues post-operative central vascular surgery, increasing morbidity and costs. Though smaller, a few trials have shown positive results for Omega-3 fatty acids. This ...
FORWARD Trial: Use of Omega 3 to prevent recurring atrial fibrillation
Atrial fibrillation (AF) is a very prevalent arrhythmia and there is no known drug, device or ablation technique effective enough to treat it. Omega 3 fatty acids have electrophysiological, ...
Atrial fibrillation (AF) is a very prevalent arrhythmia and there is no known drug, device or ablation technique effective enough to treat it. Omega 3 fatty acids have electrophysiological, ...
Monoclonal antibodies for the treatment of dislipidemia in patients on maximal dose statins.
Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite the maximal dose or because of adverse effects. Monoclonal antibody RN316 ...
Statins are first-line therapy for hypercholesterolemia. However, many patients are not able to achieve their goals despite the maximal dose or because of adverse effects. Monoclonal antibody RN316 ...
DALCETRAPIB: Dalcetrabib for the treatment of ACS
High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased HDL 30% from baseline. The objective was to test dalcetrapib in the context of ...
High levels of HDL are known to exert a protective effect. In previous studies, dalcetrapib administration increased HDL 30% from baseline. The objective was to test dalcetrapib in the context of ...
SWISS AMI: Stem cells infusion after primary angioplasty
The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo, to receive early (before 7 days) or late (after 7 days) stem cells infusion. Primary ...
The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo, to receive early (before 7 days) or late (after 7 days) stem cells infusion. Primary ...
PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.
Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals and mitochondrial damage. It has ...
Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals and mitochondrial damage. It has ...
ALCADIA: An intra-myocardial injection of autologous cardiac derived stem cells improves ventricular function in patients with ischemic cardiomyopathy.
This is an open trial that included 7 patients with ischemic cardiomyopathy and reduced the ejection fraction (between15% and 35%) administered via intra-myocardial injection with autologous cardiac ...
This is an open trial that included 7 patients with ischemic cardiomyopathy and reduced the ejection fraction (between15% and 35%) administered via intra-myocardial injection with autologous cardiac ...
SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.
This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced ejection fraction (lower than 40%) ...
This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced ejection fraction (lower than 40%) ...
POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.
Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial randomized 30 patients with LV dysfunction due to ischemic cardiomyopathy to receive ...
Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial randomized 30 patients with LV dysfunction due to ischemic cardiomyopathy to receive ...
TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.
This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) <45%. An intracoronary infusion with fixed doses ...
This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) <45%. An intracoronary infusion with fixed doses ...